Alexey Ruzin
Infectious Diseases
Biosynthetic Chemistry
Wyeth Research
Pearl River
USA
Name/email consistency: high
- Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489. Ruzin, A., Petersen, P.J., Jones, C.H. J. Antimicrob. Chemother. (2010)
- Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Ruzin, A., Immermann, F.W., Bradford, P.A. Antimicrob. Agents Chemother. (2008)
- AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Ruzin, A., Keeney, D., Bradford, P.A. J. Antimicrob. Chemother. (2007)
- AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Ruzin, A., Keeney, D., Bradford, P.A. Antimicrob. Agents Chemother. (2005)
- Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Ruzin, A., Visalli, M.A., Keeney, D., Bradford, P.A. Antimicrob. Agents Chemother. (2005)
- Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Ruzin, A., Singh, G., Severin, A., Yang, Y., Dushin, R.G., Sutherland, A.G., Minnick, A., Greenstein, M., May, M.K., Shlaes, D.M., Bradford, P.A. Antimicrob. Agents Chemother. (2004)